Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Liabilities and Shareholders Equity: 2015-2025

Historic Liabilities and Shareholders Equity for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to $143.5 million.

  • Seres Therapeutics' Liabilities and Shareholders Equity fell 19.73% to $143.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $591.3 million, marking a year-over-year decrease of 50.74%. This contributed to the annual value of $139.8 million for FY2024, which is 61.01% down from last year.
  • Seres Therapeutics' Liabilities and Shareholders Equity amounted to $143.5 million in Q3 2025, which was down 0.23% from $143.8 million recorded in Q2 2025.
  • Seres Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $406.4 million during Q2 2023, with a 5-year trough of $139.8 million in Q4 2024.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $270.2 million (2023), whereas its average is $257.8 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first spiked by 176.35% in 2021, then plummeted by 61.01% in 2024.
  • Seres Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $354.9 million in 2021, then declined by 1.71% to $348.8 million in 2022, then rose by 2.81% to $358.6 million in 2023, then crashed by 61.01% to $139.8 million in 2024, then fell by 19.73% to $143.5 million in 2025.
  • Its last three reported values are $143.5 million in Q3 2025, $143.8 million for Q2 2025, and $164.2 million during Q1 2025.